Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 14/20 | 0.44 |
| ▸ | MIF | P14174 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1096474 | 0.89 | NPC1 (0.52) | F10NPC1RAB9A | |
| SCHEMBL1095450 | 0.87 | F10 (0.48) | F10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1101328 | 0.87 | F10 (0.46) | F10MIFNPC1RAB9AHDAC6 | |
| SCHEMBL1002307 | 0.87 | F10 (0.46) | F10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1096472 | 0.86 | F10 (0.55) | F10 | |
| SCHEMBL1096286 | 0.86 | F10 (0.48) | F10MIFNPC1RAB9A | |
| SCHEMBL1095599 | 0.86 | F10 (0.47) | F10NPC1RAB9A | |
| SCHEMBL1095841 | 0.84 | F10 (0.46) | F10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1097180 | 0.84 | RAB9A (0.60) | MIFNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1096261 | 0.83 | F10 (0.50) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153670-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20090298806-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| US-7521470-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298806-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | F10 8/4885MIF 997/4885NPC1 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.